Forte Depreciation And Amortization vs Net Income From Continuing Ops Analysis

FBRX Stock

USD 21.71 1.92 9.70%

Forte Biosciences financial indicator trend analysis is much more than just examining Forte Biosciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Forte Biosciences is a good investment. Please check the relationship between Forte Biosciences Depreciation And Amortization and its Net Income From Continuing Ops accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Forte Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.

Depreciation And Amortization vs Net Income From Continuing Ops

Depreciation And Amortization vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Forte Biosciences Depreciation And Amortization account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Forte Biosciences' Depreciation And Amortization and Net Income From Continuing Ops is 0.59. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Forte Biosciences, assuming nothing else is changed. The correlation between historical values of Forte Biosciences' Depreciation And Amortization and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Forte Biosciences are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Depreciation And Amortization i.e., Forte Biosciences' Depreciation And Amortization and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

0.59

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Net Income From Continuing Ops

Most indicators from Forte Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Forte Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Forte Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.Selling General Administrative is likely to drop to about 7.6 M in 2024. Tax Provision is likely to drop to 855.00 in 2024

	2023	2024 (projected)
Depreciation And Amortization	9K	8.6K
Interest Income	1.1M	1.3M

Depreciation And Amortization Interest Income

Forte Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.52	0.55	0.64	0.83	0.7	-0.06	-0.74	0.57	0.33	0.69	-0.04	0.32	-0.38	1.0	0.92	-0.24	0.83	-0.38	0.45	-0.15	0.84	0.74	0.6	0.7	1.0
Short Long Term Debt Total	0.52		0.79	0.59	0.03	0.67	0.62	-0.56	0.56	-0.34	0.9	0.71	0.87	-0.32	0.49	0.32	0.31	0.68	-0.32	0.9	-0.63	0.56	0.7	0.91	0.67	0.49
Other Current Liab	0.55	0.79		0.93	0.13	0.77	0.35	-0.81	0.74	-0.09	0.84	0.38	0.62	-0.45	0.52	0.25	0.18	0.47	-0.45	0.58	-0.29	0.65	0.75	0.82	0.77	0.52
Total Current Liabilities	0.64	0.59	0.93		0.31	0.75	0.2	-0.84	0.75	0.04	0.7	0.09	0.4	-0.58	0.62	0.35	0.13	0.49	-0.58	0.41	-0.13	0.71	0.68	0.72	0.75	0.62
Total Stockholder Equity	0.83	0.03	0.13	0.31		0.35	-0.49	-0.53	0.24	0.6	0.25	-0.44	-0.15	-0.22	0.85	0.88	-0.62	0.54	-0.22	-0.08	0.17	0.62	0.46	0.06	0.35	0.85
Property Plant And Equipment Net	0.7	0.67	0.77	0.75	0.35		0.06	-0.77	0.97	0.23	0.88	0.13	0.32	-0.04	0.68	0.54	0.21	0.48	-0.04	0.62	0.09	0.53	0.76	0.77	1.0	0.68
Net Debt	-0.06	0.62	0.35	0.2	-0.49	0.06		-0.06	0.04	-0.93	0.29	0.66	0.77	-0.4	-0.09	-0.18	0.74	0.42	-0.4	0.67	-0.79	0.25	0.21	0.6	0.06	-0.08
Retained Earnings	-0.74	-0.56	-0.81	-0.84	-0.53	-0.77	-0.06		-0.73	-0.13	-0.7	0.11	-0.27	0.32	-0.72	-0.6	0.08	-0.53	0.32	-0.31	0.0	-0.73	-0.9	-0.57	-0.78	-0.73
Accounts Payable	0.57	0.56	0.74	0.75	0.24	0.97	0.04	-0.73		0.21	0.78	0.05	0.19	0.0	0.55	0.39	0.3	0.32	0.0	0.52	0.22	0.46	0.67	0.7	0.97	0.55
Cash	0.33	-0.34	-0.09	0.04	0.6	0.23	-0.93	-0.13	0.21		0.04	-0.49	-0.54	0.31	0.35	0.37	-0.7	-0.18	0.31	-0.38	0.68	-0.02	0.02	-0.28	0.23	0.35
Non Current Assets Total	0.69	0.9	0.84	0.7	0.25	0.88	0.29	-0.7	0.78	0.04		0.52	0.68	-0.14	0.66	0.48	0.15	0.62	-0.14	0.8	-0.31	0.65	0.79	0.89	0.88	0.67
Non Currrent Assets Other	-0.04	0.71	0.38	0.09	-0.44	0.13	0.66	0.11	0.05	-0.49	0.52		0.84	-0.13	-0.07	-0.25	0.35	0.26	-0.13	0.72	-0.74	0.15	0.08	0.58	0.13	-0.06
Other Assets	0.32	0.87	0.62	0.4	-0.15	0.32	0.77	-0.27	0.19	-0.54	0.68	0.84		-0.42	0.29	0.13	0.34	0.64	-0.42	0.84	-0.87	0.51	0.49	0.81	0.31	0.3
Long Term Debt	-0.38	-0.32	-0.45	-0.58	-0.22	-0.04	-0.4	0.32	0.0	0.31	-0.14	-0.13	-0.42		-0.38	-0.18	-0.04	-0.56	1.0	-0.19	0.58	-0.57	-0.15	-0.38	-0.04	-0.39
Cash And Short Term Investments	1.0	0.49	0.52	0.62	0.85	0.68	-0.09	-0.72	0.55	0.35	0.66	-0.07	0.29	-0.38		0.93	-0.26	0.82	-0.38	0.42	-0.13	0.83	0.73	0.57	0.68	1.0
Common Stock Total Equity	0.92	0.32	0.25	0.35	0.88	0.54	-0.18	-0.6	0.39	0.37	0.48	-0.25	0.13	-0.18	0.93		-0.3	0.78	-0.18	0.31	-0.03	0.67	0.68	0.37	0.54	0.93
Common Stock Shares Outstanding	-0.24	0.31	0.18	0.13	-0.62	0.21	0.74	0.08	0.3	-0.7	0.15	0.35	0.34	-0.04	-0.26	-0.3		0.08	-0.04	0.54	-0.24	-0.07	0.02	0.48	0.21	-0.25
Short Term Investments	0.83	0.68	0.47	0.49	0.54	0.48	0.42	-0.53	0.32	-0.18	0.62	0.26	0.64	-0.56	0.82	0.78	0.08		-0.56	0.69	-0.61	0.79	0.66	0.72	0.48	0.83
Long Term Debt Total	-0.38	-0.32	-0.45	-0.58	-0.22	-0.04	-0.4	0.32	0.0	0.31	-0.14	-0.13	-0.42	1.0	-0.38	-0.18	-0.04	-0.56		-0.19	0.58	-0.57	-0.15	-0.38	-0.04	-0.39
Non Current Liabilities Total	0.45	0.9	0.58	0.41	-0.08	0.62	0.67	-0.31	0.52	-0.38	0.8	0.72	0.84	-0.19	0.42	0.31	0.54	0.69	-0.19		-0.61	0.44	0.54	0.93	0.62	0.42
Capital Surpluse	-0.15	-0.63	-0.29	-0.13	0.17	0.09	-0.79	0.0	0.22	0.68	-0.31	-0.74	-0.87	0.58	-0.13	-0.03	-0.24	-0.61	0.58	-0.61		-0.38	-0.18	-0.51	0.09	-0.13
Other Current Assets	0.84	0.56	0.65	0.71	0.62	0.53	0.25	-0.73	0.46	-0.02	0.65	0.15	0.51	-0.57	0.83	0.67	-0.07	0.79	-0.57	0.44	-0.38		0.72	0.63	0.53	0.84
Other Stockholder Equity	0.74	0.7	0.75	0.68	0.46	0.76	0.21	-0.9	0.67	0.02	0.79	0.08	0.49	-0.15	0.73	0.68	0.02	0.66	-0.15	0.54	-0.18	0.72		0.69	0.76	0.73
Total Liab	0.6	0.91	0.82	0.72	0.06	0.77	0.6	-0.57	0.7	-0.28	0.89	0.58	0.81	-0.38	0.57	0.37	0.48	0.72	-0.38	0.93	-0.51	0.63	0.69		0.77	0.57
Property Plant And Equipment Gross	0.7	0.67	0.77	0.75	0.35	1.0	0.06	-0.78	0.97	0.23	0.88	0.13	0.31	-0.04	0.68	0.54	0.21	0.48	-0.04	0.62	0.09	0.53	0.76	0.77		0.68
Total Current Assets	1.0	0.49	0.52	0.62	0.85	0.68	-0.08	-0.73	0.55	0.35	0.67	-0.06	0.3	-0.39	1.0	0.93	-0.25	0.83	-0.39	0.42	-0.13	0.84	0.73	0.57	0.68

Click cells to compare fundamentals

Forte Biosciences Account Relationship Matchups

Forte Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.7M	61.2M	43.3M	42.0M	39.0M	43.2M
Other Current Liab	343.2K	1.0M	812K	2.0M	2.2M	4.0M
Total Current Liabilities	1.9M	2.3M	1.8M	3.2M	3.7M	6.0M
Total Stockholder Equity	(4.8M)	59.0M	41.5M	38.8M	35.3M	42.2M
Property Plant And Equipment Net	4.0M	150.6K	97K	0.0	109K	103.6K
Net Debt	1.8M	(58.8M)	(42.0M)	(41.1M)	(12.0M)	(12.6M)
Retained Earnings	(5.0M)	(51.5M)	(73.2M)	(87.0M)	(118.5M)	(124.4M)
Accounts Payable	1.6M	1.2M	946K	1.2M	1.4M	1.3M
Cash	6.9M	58.8M	42.0M	41.1M	12.0M	11.4M
Non Current Assets Total	150.6K	1.3M	786K	486K	653K	620.4K
Other Assets	227K	1.4M	0.0	1.0	0.9	0.86
Cash And Short Term Investments	6.9M	58.8M	42.0M	41.1M	37.1M	41.0M
Common Stock Total Equity	20K	23K	1K	13K	11.7K	9.9K
Common Stock Shares Outstanding	2.1M	294.4K	558.7K	695.3K	1.3M	862.0K
Short Term Investments	52.8M	55.3M	12.8M	25.2M	22.6M	29.7M
Liabilities And Stockholders Equity	7.7M	61.2M	43.3M	42.0M	39.0M	43.2M
Non Current Liabilities Total	28.4M	10.5M	1.2M	946K	1.2M	0.0
Other Current Assets	53.2K	1.1M	476K	411K	1.2M	831.3K
Other Stockholder Equity	(10.3M)	49.2M	71.4M	125.8M	153.8M	96.1M
Total Liab	12.4M	2.3M	1.8M	3.2M	3.7M	3.5M
Property Plant And Equipment Gross	4.0M	150.6K	97K	0.0	118K	112.1K
Total Current Assets	7.5M	59.9M	42.5M	41.5M	38.3M	41.8M
Accumulated Other Comprehensive Income	10K	(61.2M)	(43.3M)	4K	3.6K	3.8K
Common Stock	23K	1K	13K	21K	36K	37.8K
Property Plant Equipment	1.2M	4.0M	152K	97K	87.3K	82.9K
Net Tangible Assets	(4.8M)	59.0M	41.5M	38.8M	44.6M	29.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Forte Stock Analysis

When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Forte Depreciation And Amortization vs Net Income From Continuing Ops Analysis

Depreciation And Amortization vs Net Income From Continuing Ops

Depreciation And Amortization vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Depreciation And Amortization

Net Income From Continuing Ops

Forte Biosciences fundamental ratios Correlations

Forte Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Forte Biosciences fundamental ratios Accounts

Also Currently Popular

Additional Tools for Forte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Long Term Debt
Total Current Assets	+ 1.0	Cash And Short Term Investments
Accounts Payable	+ 0.97	Property Plant And Equipment Net

Cash	- 0.93	Net Debt
Other Stockholder Equity	- 0.9	Retained Earnings
Capital Surpluse	- 0.87	Other Assets
Retained Earnings	- 0.84	Total Current Liabilities
Retained Earnings	- 0.81	Other Current Liab
Capital Surpluse	- 0.79	Net Debt